We also suggest utilizing these four flavonoids in the development of antibody-drug conjugates (ADCs) and proteolysis-targeting-chimera (PROTAC) technologies for the effective treatment of KRAS G12D mutated cancers in the near future. The gene discussed is KRAS; the disease is cancer.